Modality
ASO
MOA
Menini
Target
TNFα
Pathway
STING
PsA
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
Sep 2017
→ Oct 2030
Phase 1Current
NCT06687237
2,852 pts·PsA
2017-09→2030-10·Active
2,852 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-253mo awayAdCom· PsA
2030-10-224.6y awayInterim· PsA
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Active
Catalysts
AdCom
2026-06-25 · 3mo away
PsA
Interim
2030-10-22 · 4.6y away
PsA
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06687237 | Phase 1 | PsA | Active | 2852 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα | |
| VKT-4052 | Viking Therapeutics | Phase 2/3 | TNFα | |
| Olpafutibatinib | Immunocore | Approved | SMN2 |